Slow-release oxprenolol compared with oxprenolol in hypertensive patients

A multicenter clinical trial

Barry J Materson, B. A. Friedman, K. M. Hla, B. S. Neidorf, J. M. Gray, N. Glazer, S. Gross

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

Original languageEnglish
Pages (from-to)51-54
Number of pages4
JournalDrug Intelligence and Clinical Pharmacy
Volume17
Issue number1
StatePublished - Feb 14 1983
Externally publishedYes

Fingerprint

Oxprenolol
Multicenter Studies
Clinical Trials
Blood Pressure
Placebos
Hypertension
Sympathomimetics
Adrenergic Antagonists
Hydrochlorothiazide
Random Allocation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Materson, B. J., Friedman, B. A., Hla, K. M., Neidorf, B. S., Gray, J. M., Glazer, N., & Gross, S. (1983). Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial. Drug Intelligence and Clinical Pharmacy, 17(1), 51-54.

Slow-release oxprenolol compared with oxprenolol in hypertensive patients : A multicenter clinical trial. / Materson, Barry J; Friedman, B. A.; Hla, K. M.; Neidorf, B. S.; Gray, J. M.; Glazer, N.; Gross, S.

In: Drug Intelligence and Clinical Pharmacy, Vol. 17, No. 1, 14.02.1983, p. 51-54.

Research output: Contribution to journalArticle

Materson, BJ, Friedman, BA, Hla, KM, Neidorf, BS, Gray, JM, Glazer, N & Gross, S 1983, 'Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial', Drug Intelligence and Clinical Pharmacy, vol. 17, no. 1, pp. 51-54.
Materson BJ, Friedman BA, Hla KM, Neidorf BS, Gray JM, Glazer N et al. Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial. Drug Intelligence and Clinical Pharmacy. 1983 Feb 14;17(1):51-54.
Materson, Barry J ; Friedman, B. A. ; Hla, K. M. ; Neidorf, B. S. ; Gray, J. M. ; Glazer, N. ; Gross, S. / Slow-release oxprenolol compared with oxprenolol in hypertensive patients : A multicenter clinical trial. In: Drug Intelligence and Clinical Pharmacy. 1983 ; Vol. 17, No. 1. pp. 51-54.
@article{2919f6ae238b4e779ddcd8f7528eeef6,
title = "Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial",
abstract = "Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.",
author = "Materson, {Barry J} and Friedman, {B. A.} and Hla, {K. M.} and Neidorf, {B. S.} and Gray, {J. M.} and N. Glazer and S. Gross",
year = "1983",
month = "2",
day = "14",
language = "English",
volume = "17",
pages = "51--54",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "1",

}

TY - JOUR

T1 - Slow-release oxprenolol compared with oxprenolol in hypertensive patients

T2 - A multicenter clinical trial

AU - Materson, Barry J

AU - Friedman, B. A.

AU - Hla, K. M.

AU - Neidorf, B. S.

AU - Gray, J. M.

AU - Glazer, N.

AU - Gross, S.

PY - 1983/2/14

Y1 - 1983/2/14

N2 - Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

AB - Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0020683196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020683196&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 51

EP - 54

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 1

ER -